As non-steroidal anti-inflammatory drugs have become more widely used, replacing simple analgesics for the treatment of minor musculoskeletal disorders, concern has grown about their toxicity. Some adverse effects, such as gastrointestinal haemorrhage and functional renal impairment, are thought to be a consequence of the pharmacological action of the drugs, while others such as hepatocellular damage and haematological reactions seem to be due to idiosyncratic or hypersensitivity reactions. Hepatic reactions have been reported with most nonsteroidal anti-inflammatory drugs and recently the Food and Drug Administration in the United States has declared them a 'class effect."`In clinical trials of diclofenac an incidence of abnormal liver function tests of 2 to 4% has been recorded, which was reported to be higher than with the comparison drugs.2 Most of these reactions, however, were asymptomatic and, as with other members of this class of drugs, reports of clinically important reactions have described only a few cases."
Non-steroidal anti-inflammatory drugs are used extensively in Australia, and in recent years diclofenac has maintained a consistently high market share. During this period the Adverse Drug Reactions Advisory Committee has received a larger number of reports of hepatic reactions to diclofenac than to any other drug. In this paper we review these reports with particular attention to the strength of the association between diclofenac use and liver injury, the clinical and biochemical features of the patients, and the question of whether there are any predictors of the severity of the reactions and the duration of the recovery period.
Patients and methods
We reviewed all cases of hepatic dysfunction associated with the use of diclofenac reported to Adverse Drug Reactions Advisory Committee between March 1981 (the date marketing started in Australia) and April 1989. The committee collects detailed information on all serious adverse drug reactions identified through the national voluntary reporting scheme. This information includes the dates of starting and stopping all drugs being used by the patient and details of dosage, age, sex, and weight of the patient. Through contact with the reporter an attempt is made to collect all relevant laboratory data. In the case ofhepatic reactions this includes liver function tests, serological tests for hepatitis A and B, and, where relevant, the results of imaging procedures, the histology of any liver biopsies, and necropsy findings. Each report is reviewed by the committee, which comprises six specialist physicians, including a gastroenterologist. In this paper we review those cases for which, in the opinion of the committee, diclofenac was the sole suspected drug used by the patient before the development of the illness.
To facilitiate comparisons between individuals and across laboratories, laboratory data for total bilirubin, aspartate transaminase, alanine transaminase, serum alkaline phosphatase, and y glutamyltransferase were expressed as multiples (deviate ratios) of the upper limit of the normal range for the laboratory. For ( or log alanine transaminase) against time. The mean recovery phase transaminase activity can then be calculated from the ratio of the total area under the transaminase versus time curve during the recovery phase to the total duration of the recovery phase.
In cases where accurate information on daily dose and duration of administration of diclofenac enabled calculation of the total dose taken, these estimates ofthe cumulative dose were used as the independent variable in regression analysis against peak and mean transaminase activities. Because of the skewed frequency distribution of the data, log transformations were used. The coefficient of determination, the coefficient of regression, and the F statistic were calculated Log dose of diclofenac Figure 3 : Relation between diclofenac dose and severity ofliver damage as reflected by peak aspartate transaminase (AST) levels (expressed as deviate ratios). There was a significant relation between log dose and log DRAST: r2=0 68, slope 0.91, p=00001. the time diclofenac treatment was withdrawn. When regression analysis was performed the data were fitted well by exponential functions (for regression data see Figs 1 and 2 ). The slopes of the two exponents are equivalent to postpeak half lives for aspartate and alanine transaminases of 13-7 and 13-2 days respectively.
RELATION BETWEEN CUMULATIVE DOSE AND SEVERITY OF LIVER DAMAGE
In cases where there were complete data, the relation between cumulative dose of diclofenac assumed to have been taken and the severity of the hepatic injury was examined by regressing the log peak aspartate transaminase and alanine transaminase values (expressed as deviate ratios) on log cumulative dose. As the data in Figures 3  and 4 show, there was a significant correlation between cumulative dose and effect with both of these parameters. This exercise was repeated by regressing mean values for both on log cumulative dose, and once again significant correlations were found: mean aspartate transaminase r2=0.49, p=0Q003; mean alanine transaminase r2=059, p=0.006.
Correlations between other measures of diclofenac exposure and the severity of liver damage were not high as the following statistics show. Regression of log peak aspartate transaminase and alanine transaminase on duration of treatment r2=0 18, p=007 and r2=0.22, p=011, respectively; regression of log peak aspartate transaminase and alanine transaminase on daily dose: r2=0 13, p=0O15 and r2=008, p=034 respectively. Attempts to correlate log cumulative dose with other measures of liver injury were also relatively unrewarding. Log serum alkaline phosphatase r2=0094, p=0.23; log y glutamyltransferase r2=0350, p=0-01; log bilirubin r2=O029, p=0.01. We are unable therefore to say whether serious liver injury is a more common complication with diclofenac than with other non-steroidal antiinflammatory drugs. This highlights the need for more openness on the part of pharmaceutical manufacturers, and properly controlled pharmacoepidemiological studies of the various serious adverse effects of these commonly used drugs.
The most surprising finding in this series was the correlation between the total dose of diclofenac reported to have been taken and the biochemical measure ofthe severity ofthe hepatic lesion. The explanation is not clear, but in view of the absence of the typical features of drug hypersensitivity in the Australian cases the finding may indicate that for some patients this reaction is a direct toxic effect of the drug. This possibility has been suggested previously.3 ' Impaired metabolic clearance resulting in accumulation of diclofenac or a metabolite, or formation ofa toxic reactive metabolite, could be an explanation, and such a trait could be genetically determined. As diclofenac is rapidly eliminated and the onset of hepatotoxicity was often delayed we favour accumulation of a metabolite as the explanation for this observation.
